期刊文献+

肺癌侵袭和转移相关因子表达机制的研究 被引量:1

Correlation between the expressions of metastasis related factors and the invasion of bronchogenic carcinoma
下载PDF
导出
摘要 目的探讨MMP-2、MMP-9、Fas、HIF-lα、VEGF在肺癌组织中的表达,研究其与肺癌的侵袭和转移的关系。方法对我院经根治性切除的肺癌,术后得到病理证实患者,进行肺癌侵袭和转移相关因子研究,采用肺癌组织石蜡切片进行免疫组化分析。结果研究发现69例肺癌组织中MMP-2、MMP-9、Fas、HIF-lα、VEGF蛋白阳性表达总蹬阳性率分别为86.9%、88.4%、57.9%、81.2%、82.6%,其蛋白的阳性表达与临床分期、复发转移、分化程度等密切相关。结论MMP-2、MMP-9、Fas、HIF-lα、VEGF蛋白表达与肺癌侵袭与转移机制关系密切,尝可能成为判断肺癌治疗效果和预后的可靠指标之一。 Objective To observe the expressions of MMP-2, MMP-9, Fas, HIF-1α, VEGF in bronchogenic carcinoma tissue, and to investigate the relationship between these factors and invasion as well as metastasis of bronchogenic carcinoma. Methods 69 patients who were enrolled in our hospital were treated with radical excision and identified as bronchogenic carcinoina by pathology. The expressions of MMP-2, MMP-9, Fas, HIF-1α, VEGF were detected by method. Results The positive expression rates of MMP-2, MMP-9, Fas, HIF-1α, VEGF in bronchogenic carcinoma tissue were 86.9%, 88.4%, 57.9%, 81.2%, 82.6%, respectively. The expression levels were related with clinical stage, palindromia or metastasis, histological differentiation. Conclusion The expression of MMP-2, MMP-9, Fas, HIF-1α, VEGF in brenchogenic carcinoma tissue is closely related with the invasion and metastasis mechanism of bronchogenic carcinoma, which can serve as one of the indexes for evaluating the therapeutic effect and prognosis in patients with bronchogenic carcinoma.
作者 石青
出处 《河北医药》 CAS 2009年第8期904-906,共3页 Hebei Medical Journal
关键词 肺癌 侵袭 转移 机制 bronchogenic carcinoma invasion metastasis mechanism
  • 相关文献

参考文献6

二级参考文献40

  • 1Wang Yahong,J Bio Chem,1999年,274卷,46期,33043页 被引量:1
  • 2Orlow I, Park B, Clas B, et al. Genetic instability, response to DNA damage, and repair capacity in individuals with multiple primary non-small cell lung cancers. Lung Cancer,2005,49(Suppl 2):S21(O-54). 被引量:1
  • 3Chan T, MacAulay C, Lam W, et al. Finding biomarker specific for early stages of lung cancer using SAGE data. Lung Cancer,2005,49(Suppl 2):S8(O-014). 被引量:1
  • 4Hirano T, Ohira T, Suga Y, et al. Quantitative proteomic exploration of biomarkers for early detection of adenocarcinoma of the lung. Lung Cancer,2005,49(Suppl 2):S179(P-247). 被引量:1
  • 5Suga Y, Miyajima K, Honda J, et al. Detection of aberrant p16 promotor methylation of tumor suppressor genes in serum DNA from non-small cell lung cancer patients using real-time PCR. Lung Cancer,2005,49(Suppl 2):S84(PD-061). 被引量:1
  • 6Rosell A, Rodriguez N, Lioret J, et al. Dysplasia and aberrant DNA methylation profiles in risks and lung cancer patients. Lung Cancer,2005,49(Suppl 2):S186(P-272). 被引量:1
  • 7Molina J, Adjec A. Validation of a pre-selected panel of methylated genes in lung cancer as "cancer only" markers. Lung Cancer,2005,49(Suppl 2):S184(PD-266). 被引量:1
  • 8MacAulay C, Lonergan K, Garnis C, et al. Combining genome wide (BACarray CGH and Serial analysis of gene expression) and quantitative microscopy for the analysis of lung cancer and its precursors. Lung Cancer,2005,49(Suppl 2):S183(P-260). 被引量:1
  • 9Davis J, Shubeler D, Lam W, et al. Comprehensive epigenomic profiling of matched normal and tumor lung cell lines. Lung Can-cer,2005,49(Suppl 2):S122(P-028). 被引量:1
  • 10Tan E, Hsu A, Eng P, et al. Molecular profiling of lung cancers: Can it be used as clinical tool? Lung Cancer,2005,49(Suppl 2):S147(P-123) . 被引量:1

共引文献17

同被引文献16

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部